# CarrierGene Biotech (Suzhou) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/carriergene-biotech-suzhou-co

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.carriergene.com
- Total disclosed funding: $92M
- Latest round: Series B (Jun 2, 2022)
- Investors on record: 15

## About

Established in 2017 and based in Suzhou, China, CarrierGene Biotech (Suzhou) Co., Ltd is a gene detection company that focuses on genetic screening and diagnosis through genetic technology and big data algorithms, providing genetic data analysis and health management recommendations. The company has offices in Houston, Shanghai and Suzhou. In February 2018, the company raised an undisclosed amount in angel funding from new investors. The company passed ISO9001 and ISO13485 quality management system certification.

The clinical product line of CarrierGene Biotech is mainly in the field of oncology and reproductive health. The company's core technologies include BDA, Toehold and QASeq. BDA technology can selectively amplify mutations in a wild-type DNA background to the extent that it can be applied to liquid tumor biopsies. Toehold technology is widely used in oncology precision medicine, pathogenic microbial detection and other applications such as the construction of molecular motors, logic gates and other nanodevices, as well as in the study of signal amplification in biosensors. QASeq is a new quantitative amplicon sequencing technology that helps developers achieve rapid development of customized NGS assays The company has cooperated with Oxford Nanopore Technologies Ltd., MD Anderson and Yale University and other enterprises.

The company will develop new genetic testing products and drive registration approval for clinical products and expand its commercial teams in China and the United States. The company will also focus on nucleic acid detection underlying technology development.

## Funding rounds

- Series B, Jun 2, 2022, $50M — Hong Shan, Pappas Capital, Yonghua Capital, Panlin Capital, BioTrack Capital, Jiangsu Tuobang Investment Management, Shanghai Deguan Asset Management, Huarun Zhengda life Science Fund, Astra Zeneca CICC Healthcare Venture Capital Fund
- Series A, Jan 11, 2021, $42M — Hong Shan, Yonghua Capital, Panlin Capital, TF Capital, CCB Private Equity Investment Management, BioTrack Capital, Jiangsu Tuobang Investment Management, Ming Bioventures, Ruomu Capital
- Angel, Feb 23, 2018 — GP Capital, Hangzhou Ruomu Zhizang Investment Management, Ruomu Capital

## Investors

- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Angel
- Hangzhou Ruomu Zhizang Investment Management — Angel
- Ruomu Capital — Angel, Series A
- Hong Shan — Series A, Series B
- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series A, Series B
- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series A, Series B
- TF Capital — Series A
- CCB Private Equity Investment Management (https://capitalatlas.ai/funds/ccb-private-equity-investment-management) — Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A, Series B
- Jiangsu Tuobang Investment Management — Series A, Series B
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series A
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series B
- Shanghai Deguan Asset Management (https://capitalatlas.ai/funds/shanghai-deguan-asset-management) — Series B
- Huarun Zhengda life Science Fund — Series B
- Astra Zeneca CICC Healthcare Venture Capital Fund — Series B